Wells Fargo & Company Design Therapeutics, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 18,428 shares of DSGN stock, worth $75,186. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,428

Previous 14,415 27.84%

Holding current value

$75,186

Previous $77,000 46.75%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$4.56 - $7.5 $18,299 - $30,097	4,013 Added 27.84%	18,428 $113,000
Q3 2024 Nov 13, 2024	BUY	$3.19 - $5.88 $1,971 - $3,633	618 Added 4.48%	14,415 $77,000
Q2 2024 Aug 13, 2024	BUY	$3.23 - $4.77 $7,399 - $10,928	2,291 Added 19.91%	13,797 $46,000
Q1 2024 May 10, 2024	BUY	$2.27 - $4.03 $3,368 - $5,980	1,484 Added 14.81%	11,506 $46,000
Q4 2023 Feb 09, 2024	BUY	$1.99 - $2.76 $3,960 - $5,492	1,990 Added 24.78%	10,022 $26,000
Q3 2023 Nov 13, 2023	SELL	$2.05 - $8.14 $9,083 - $36,068	-4,431 Reduced 35.55%	8,032 $18,000
Q2 2023 Aug 15, 2023	BUY	$4.99 - $7.64 $32,280 - $49,423	6,469 Added 107.92%	12,463 $78,000
Q1 2023 May 12, 2023	BUY	$5.5 - $9.77 $32,967 - $58,561	5,994 New	5,994 $34,000
Q3 2022 Nov 14, 2022	SELL	$14.09 - $25.57 $422 - $767	-30 Reduced 6.88%	406 $7,000
Q2 2022 Aug 12, 2022	SELL	$9.91 - $17.33 $2,150 - $3,760	-217 Reduced 33.23%	436 $6,000
Q1 2022 May 16, 2022	SELL	$11.17 - $20.89 $103,769 - $194,068	-9,290 Reduced 93.43%	653 $10,000
Q4 2021 Feb 14, 2022	BUY	$13.64 - $21.41 $135,622 - $212,879	9,943 New	9,943 $213,000

Others Institutions Holding DSGN

# of Institutions

100

Shares Held

31.5M

Call Options Held

2.3K

Put Options Held

2.7K

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $228M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Design Therapeutics, Inc. Transaction History